|
Asymptomatic Carotid Artery Plaque Study (ACAPS) Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Asymptomatic Carotid Artery Plaque Study (ACAPS) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Asymptomatic Carotid Artery Plaque Study (ACAPS) Clinical research trials and Asymptomatic Carotid Artery Plaque Study (ACAPS) health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Asymptomatic Carotid Artery Plaque Study (ACAPS). Asymptomatic Carotid Artery Plaque Study (ACAPS) Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Asymptomatic Carotid Artery Plaque Study (ACAPS) clinical trial. Human subjects frequently get the finest healthcare available for their Asymptomatic Carotid Artery Plaque Study (ACAPS) condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Asymptomatic Carotid Artery Plaque Study (ACAPS)  Asymptomatic Carotid Artery Plaque Study (ACAPS)
Asymptomatic Carotid Artery Plaque Study (ACAPS)
For Condition: Cardiovascular Diseases,Carotid Stenosis,Cerebral Arteriosclerosis,Cerebrovascular Disorders,Heart Diseases,Vascular Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.
Details: BACKGROUND: At the present time, atherosclerosis of the major extracranial arteries to the brain is considered the cause of most strokes. Early intervention and stroke prevention utilized anti-coagulants such as coumadin and heparin. Results were largely equivocal due to the diverse nature of the underlying pathogenesis and due to problems that offset potential benefit. Emphasis gradually switched to aspirin and to other platelet anti-aggregant drugs because of mounting evidence that micro-emboli were a major element in transient ischemic attacks. Several studies have examined the potential benefit of aspirin in stroke prevention. The exact dose of aspirin that was maximally beneficial with minimal side effects was not completely established. There was evidence that low dose aspirin was as effective as higher doses. The American College of Chest Physicians (ACCP) made recommendations that if aspirin were issued as a primary anti-thrombotic agent, the dose should be 325 mg daily, except in patients with cerebrovascular disease in whom the lowest beneficial dose appeared to be one gram per day. The ACCP also pointed out that the risk of bleeding was substantially greater in patients with ischemic cerebrovascular disease and venous thromboembolism than in other high risk groups requiring anticoagulation. It advised that anticoagulant therapy was not needed, but that aspirin might be given at 325 mg per day. Lovastatin is a fungal metabolite that inhibits 3-hydroxy, 3-methyl glutaryl coenzyme A reductase, the rate-limiting enzyme of cholesterol biosynthesis in human cells including the liver. Inhibition of this pathway causes the cells to increase their low density lipoprotein receptor numbers to compensate, causing a reduction in circulating low density lipoprotein levels with a consequent drop in circulating plasma cholesterol levels. The drug also raises high density lipoprotein levels significantly. A favorable outcome of the trial will have major public health implications for the prevention and control of atherosclerosis and its complications. DESIGN NARRATIVE: Randomized, double-blind, factorial design. In this multicenter study, patients were assigned to one of four drug combination groups: active lovastatin/active warfarin, active lovastatin/warfarin placebo, lovastatin placebo/active warfarin, and lovastatin placebo/warfarin placebo. Daily aspirin was recommended for everyone. Ultrasound was performed for screening, at baseline and semiannually thereafter. Lipid profiles were obtained at screening, at baseline, monthly for the first three months, at six months, and annually thereafter, with beta quantification at baseline. Recruitment began in the tenth month of the trial and continued for one year, ending in September 1990. Treatment continued through the 51st month. Average treatment period was 2.7 years. Subjects were offered a dietary regimen for three months prior to receiving any drug therapy. Only those individuals whose lipid levels did not fall below a certain point continued in dietary intervention. The primary outcome measure was the three year change in mean maximum intimal-medial thickness (IMT) in twelve walls of the carotid arteries. Secondary outcomes included change in single maximum IMT and incidence of major cardiovascular events. In 1995, an R03 was awarded to Mark Espeland to extend analyses of the carotid B-mode ultrasound data through August, 1998.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 40 Years/79 Years
Genders: Both
Protocol Entry Criteria: Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol between the 60th and 90th percentiles.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarkEspeland, , Bowman Gray School of Medicine
Additional Information:
Study ID Numbers: 58;
Study Start Date: May 1988
Record last reviewed: April 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000469
Other Vascular Diseases Studies:
1. Trial of Aspirin and Vitamin E in Women (Women's Health Study - WHS)
2. Asymptomatic Carotid Artery Plaque Study (ACAPS)
3. Treatment of Hypertension
4. Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)
5. Hypertension Detection and Follow-up Program (HDFP)
Related Studies:
Other Vascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Asymptomatic Carotid Artery Plaque Study (ACAPS)
|
|
|
|
|
|
|
|
